-Dragonfly Therapeutics to Present Phase 1 Results of DF1001 Monotherapy at ASCO Annual Meeting 2023
An oral presentation titled “Phase 1/2 Study of DF1001, a TriNKET® Anti-HER2 Targeted Immunomodulator, in Patients With Advanced Solid Tumors: Phase 1 DF1001 Monotherapy Dose Escalation Results” will be delivered by Howard Safran, MD during ASCO Developmental Therapeutics – Immunotherapy Session on June 4.
WALTHAM, Mass., June 2, 2023/PRNewswire/ — Dragonfly Therapeutics, Inc., a clinical-stage biotechnology company developing novel immunotherapies, today announced an oral presentation of the results of Phase 1 monotherapy dose escalation of DF1001 scheduled for Sunday, June 4, from 11:45 to 11:57 a.m. The presentation will take place at the Arie Crown Theater at the McCormick Place Convention Center in Chicago for the 2023 ASCO Annual Meeting. The presentation, ASCO Abstract 2508, will be given by Howard P. Safran, MD, Chief of Hematology/Oncology at Lifespan Cancer Institute and Medical Director of the Brown University Oncology Group. Dr. Safran is Principal Investigator in the Phase 1/2 DF1001 TriNKET® clinical trial, a pioneering human study exploring the safety, tolerability, and preliminary clinical and biologic activity of DF1001, a HER2-targeted immunotherapy in patients with tumors. advanced solids.
“We are excited to present the results of our Phase 1 DF1001 study at ASCO,” said Dr. Joseph Eid, President of Research and Development for Dragonfly Therapeutics. DF1001 is a first-in-class immunomodulatory TriNKET targeting HER2, which drives immune activation in solid tumors. DF1001 is also being evaluated in combination with nivolumab or paclitaxel nab. Clinical trial sites are open in the US, France, Belgium, Denmark and the Netherlands. More information about the trial, including eligibility criteria, can be obtained at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04143711).
About DF1001 DF1001 is an investigational frontline drug candidate that targets natural killer (NK) cell and T cell activation signals to coactivate NK receptors, where costimulation of NKG2D and CD16 results in distinctive activation and potent of NK cells. DF1001 is being evaluated in adult patients for the treatment of HER2-positive advanced solid tumors. DF1001 was discovered and developed using Dragonfly’s TriNKET platform. DF1001 has the potential to stimulate effective antitumor immunity in patients who do not qualify for or do not respond adequately to current therapies. DF1001 is the most advanced in a series of TriNKETs that Dragonfly is developing to address the large unmet needs of patients across a wide range of diseases.
About Dragonfly Dragonfly Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapies that use its novel technology to harness the body’s immune system and deliver innovative treatments to patients. In addition to its wholly-owned clinical assets and multiple clinical assets with partners, Dragonfly has an extensive pipeline of proprietary preclinical and clinical candidates, discovered through its proprietary platform, advancing to the clinical phase, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a wide range of diseases.
For more information, visit: www.dragonflytx.com https://www.linkedin.com/company/dragonfly-therapeutics-inc./ https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT: Anne Deconinck | anne@dragonflytx.com
Logo – https://mma.prnewswire.com/media/390962/4066598/Dragonfly_Therapeutics_Inc_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/asco-2023-dragonfly-therapeutics-presentara-los-resultados-de-fase-1-de-la-monoterapia-con-df1001-301841329.html
